Arbutus Biopharma, X‑Chem and Proteros biostructures Achieve First Milestone Under COVID-19 Discovery Research and License Agreement
Screening identifies several unique compound series that inhibit the SARS-CoV-2 nsp5 main protease, a validated target for the treatment of...
X‑Chem Acquires Glamorous AI — Immediately Creating a Leader in DEL-Powered AI Solutions
Combination Accelerates Outcomes in Early Drug Discovery WALTHAM, Mass.; Oct. 28, 2021 – X-Chem, the pioneer of DNA-encoded library (DEL)...
X‑Chem Acquires ComInnex
Extending Functional and Global Leadership in Small Molecule Drug Discovery WALTHAM, Mass.; Oct. 25, 2021 – X-Chem, the pioneer of...
LEO Pharma and X‑Chem Enter Into Discovery Research Agreement
Multi-target Collaboration to Focus on Identification of Novel Small Molecules for Anti- inflammatory Applications BALLERUP, Denmark, and WALTHAM, Mass., US;...
X‑Chem Announces OpenDEX DNA-Encoded Library Screening
Flexible and Cost-Effective Solution for Screening Billions of Small Molecules WALTHAM, Mass.; May 11, 2021 (Business Wire) – X-Chem, the...
Arbutus Biopharma, X‑Chem and Proteros biostructures Enter into a Pan-Coronavirus Discovery Research and License Agreement
Collaboration formed to accelerate the discovery of novel oral inhibitors targeting the SARS-CoV-2 nsp5 main protease for the treatment of...
X‑Chem Enters into Multitarget Oncology Discovery Research Collaboration and License Agreement with Genentech
Collaboration Includes Licensing of Preclinical Small Molecule Program WALTHAM, Mass.; Feb. 2, 2021 (Business Wire) – X-Chem, Inc., a global...
X‑Chem acquires IntelliSyn and sister company, AviSyn, to extend and streamline drug discovery service range
Acquisition allows X-Chem to offer a more comprehensive, integrated, screen-to-lead drug discovery process to pharma and biotech clients IntelliSyn’s Founder...
Servier and X‑Chem Announce Drug Discovery Collaboration in Neurological Diseases
Paris and Waltham, Mass.; Jan. 6, 2021 (Business Wire) – Servier, a global pharmaceutical Group and X-Chem, Inc., a privately...
X‑Chem Announces Licensing of Second Drug Discovery Program to Otsuka
Waltham, Mass – January 4, 2020 – X-Chem Inc. (X-Chem), the global leader in DNA-Encoded Library (DEL) technology to identify novel drug leads, announced today that Otsuka Pharmaceutical Co., Ltd.…